- Home
- LUNG vs NKTR Comparison
LUNG vs NKTR Comparison
Compare LUNG & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- NKTR
- Stock Information
- Founded
- LUNG 1995
- NKTR 1990
- Country
- LUNG United States
- NKTR United States
- Employees
- LUNG N/A
- NKTR N/A
- Industry
- LUNG Industrial Specialties
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- NKTR Health Care
- Exchange
- LUNG Nasdaq
- NKTR Nasdaq
- Market Cap
- LUNG 65.6M
- NKTR 558.0M
- IPO Year
- LUNG 2020
- NKTR 1994
- Fundamental
- Price
- LUNG $1.59
- NKTR $49.01
- Analyst Decision
- LUNG Buy
- NKTR Strong Buy
- Analyst Count
- LUNG 7
- NKTR 6
- Target Price
- LUNG $7.66
- NKTR $81.67
- AVG Volume (30 Days)
- LUNG 543.0K
- NKTR 1.1M
- Earning Date
- LUNG 10-29-2025
- NKTR 11-06-2025
- Dividend Yield
- LUNG N/A
- NKTR N/A
- EPS Growth
- LUNG N/A
- NKTR N/A
- EPS
- LUNG N/A
- NKTR N/A
- Revenue
- LUNG $90,549,000.00
- NKTR $74,934,000.00
- Revenue This Year
- LUNG $10.30
- NKTR N/A
- Revenue Next Year
- LUNG $14.72
- NKTR N/A
- P/E Ratio
- LUNG N/A
- NKTR N/A
- Revenue Growth
- LUNG 18.24
- NKTR N/A
- 52 Week Low
- LUNG $1.47
- NKTR $6.48
- 52 Week High
- LUNG $9.37
- NKTR $50.53
- Technical
- Relative Strength Index (RSI)
- LUNG 39.07
- NKTR 84.46
- Support Level
- LUNG $1.60
- NKTR $42.12
- Resistance Level
- LUNG $1.76
- NKTR $50.53
- Average True Range (ATR)
- LUNG 0.14
- NKTR 3.35
- MACD
- LUNG 0.03
- NKTR 1.68
- Stochastic Oscillator
- LUNG 4.76
- NKTR 93.63
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.